8VC led a $70m Series B round in Tempero Bio.

8VC, an investment firm, led a $70m Series B round in Tempero Bio, a clinical-stage biopharmaceutical company, with participation from Aditum Bio and Khosla Ventures. "Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year. We urgently need more effective treatments to help patients and families with these diseases. TMP-301 is a novel therapy that helps prevent relapse by targeting the underlying biology of addiction. This financing will allow us to advance TMP-301 through key proof of concept phase 2 studies in humans," Ricardo Dolmetsch, Tempero Bio President and Chief Scientific Officer.